Since many women with psychiatric disorders are or will be pregnant, medication during pregnancy is a major concern for most families. The issue of pregnancy in patients with psychiatric disorders is complex. From a eugenic point of view, it is preferable for the mother not to take any medication during pregnancy, but the reality of psychiatric treatment is that any period of discontinuation of medication increases the probability of relapse significantly. So it’s a dilemma. Although there is no evidence of any relationship between the use of psycho-psychiatric medications and the incidence of congenital malformations in the fetus, no significant effects of atypical antipsychotics on the fetus have been found. (Except in the case of psychotropic drugs with evidence of fetal harm in Class D drugs.) However, this lack of current evidence does not indicate that it is absolutely safe for pregnancy. For ethical reasons, it is not possible to study the effects of drugs on pregnancy in humans. I. The U.S. Food and Drug Administration (FDA) has promulgated criteria for grading the safety of drugs in pregnancy, which are as follows (abbreviated): Grade A: No indication of fetal harm in women in the third trimester of pregnancy. Grade B: No fetal effects were observed in animal reproductive studies (no controlled studies in pregnant women). Grade C: It was shown to have side effects on the fetus in animal studies but was not studied in women in a control group. Grade D: There is clear evidence of harm to the fetus. Grade X: It has been shown in animal or human studies to cause fetal abnormalities. Among the drugs commonly used in psychiatric clinics: clozapine, Maprotiline, Synthroid, and buspirone are grade B; promethazine, paroxetine tablets, phenobarbital, valproate, lithium salts, carbamazepine, and most tranquilizers (eszopiclone and triazolam are grade X) are grade D Most other antipsychotics and antidepressants are grade C. In 2007, the Chinese Medical Association Psychiatric Branch formulated the “Guidelines for the Prevention and Treatment of Mental Disorders in China”, which set the following principles: Women of childbearing age should take reliable and effective contraceptive measures before using psychiatric drugs, and once pregnancy is detected during the course of medication, termination of pregnancy should be considered first, and pregnancy should not be conceived until the condition is completely stable and the psychiatrist is consulted and approved. The pregnancy should be terminated once the pregnancy is discovered during the course of medication. Patients with stable disease, no past history of relapse and a high level of clinical remission may temporarily discontinue medication and wait until 12 weeks after pregnancy. For patients who do require maintenance treatment, the least toxic and safest drug for the mother and fetus may be considered and the dosage should be reduced to the lowest effective dose. Most psychotropic drugs have not been clinically proven to have a definite effect on pregnancy (with the exception of a few Class D, Division X drugs). However, adverse effects of psychotropic drugs on pregnancy cannot be ruled out. It is advisable to prohibit the use of psychiatric drugs during the 12 weeks of pregnancy. If pregnancy is to be considered, it is best if the disease has been stable for more than 2 years, there is no previous history of relapse upon reduction of medication, and the patient is currently recovering well from social functioning. Use in breastfeeding women: Almost all psychotropic drugs are secreted into breast milk, so breastfeeding women taking psychotropic drugs should avoid breastfeeding their infants and children and use other forms of breastfeeding instead.